INSIGHTS ON DRUG DEVELOPMENT

• How CRISPR And LNP Accelerate Therapeutic Innovation Through Analytics

  CRISPR gene editing and lipid nanoparticle delivery are revolutionizing precision medicine. Discover how optimized LNP systems and advanced analytics accelerate therapeutic development.

• Take The Wheel And Drive Your Oligo Synthesis Where You Want

  Explore the evolving oligo therapeutic landscape while identifying common challenges of bringing production in‑house and the key factors that shape long‑term success for smoother scale‑up.

• Development Of Separation Methods for GLP-1 Synthetic Peptides

  Peptides offer precise, low-cost therapeutic potential, especially in GLP-1 drugs for diabetes and weight loss. A new HPLC-UV/MS method ensures consistent quality and analysis of these compounds.

• Managing Endotoxins - Detect, Prevent, Remove

  Explore the risks of endotoxin contamination in drug manufacturing and discover sustainable, animal-free detection methods to ensure pharmaceutical safety and regulatory compliance.

• Improving API Solubility Using Spray Drying With Polyvinyl Alcohol

  6/5/2025

  Enhancing the solubility of poorly soluble APIs is vital for improving bioavailability. Discover how advanced formulation techniques like hot-melt extrusion and spray drying can overcome this challenge.

• Using DSC And MDSC To Study Material Interactions Of APIs And Excipients

  1/7/2026

  Thermal analysis reveals how particle size and morphology influence material interactions and stability. Learn how DSC and MDSC techniques uncover compatibility issues and guide better excipient selection.

• High Potency APIs And The Evolving Demands Of Drug Development

  4/13/2026

  See how higher API activity is changing expectations around containment, scalability, and cross‑functional alignment — and why early decisions now have a greater impact on long‑term success.

• Validation Provider Shortens The Path To Equipment Qualification

  8/19/2025

  Explore the partnership enabling Transcat to meet regulatory requirements while focusing on core R&D and accelerating the delivery of life-changing therapies.

• How The Accelerator™ Drug Development Model Enhances eNPV

  2/25/2026

  Discover how an integrated CDMO and CRO model can accelerate development timelines, add up to $62.9 million in value, and help you maximize long-term pipeline success with a single, streamlined partner.